{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:56:32Z","timestamp":1779911792523,"version":"3.53.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[1996,3,1]],"date-time":"1996-03-01T00:00:00Z","timestamp":825638400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[1996,3]]},"DOI":"10.1007\/bf02245620","type":"journal-article","created":{"date-parts":[[2005,11,14]],"date-time":"2005-11-14T23:38:09Z","timestamp":1132011489000},"page":"188-196","source":"Crossref","is-referenced-by-count":50,"title":["Clozapine versus typical antipsychotics a retro- and prospective study of extrapyramidal side effects"],"prefix":"10.1007","volume":"124","author":[{"given":"L.","family":"Peacock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lublin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Solgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"suppl","key":"BF02245620_CR1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF00442559","volume":"99","author":"DE Casey","year":"1989","unstructured":"Casey DE (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99 [suppl]:47\u201353","journal-title":"Psychopharmacology"},{"key":"BF02245620_CR2","first-page":"287","volume-title":"Schizophrenia. An integrated view","author":"DE Casey","year":"1995","unstructured":"Casey DE (1995) The nonhuman primate model: focus on dopamine D2 and serotonin mechanisms. In: Fog R, Gerlach J, Hemmingsen R (eds) Schizophrenia. An integrated view. Munksgaard, Copenhagen, pp 287\u2013297"},{"key":"BF02245620_CR3","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1192\/bjp.163.2.150","volume":"163","author":"Clozapine Study Group","year":"1993","unstructured":"Clozapine Study Group (1993) The safety and efficacy of clozapine in severe treatment-resistent schizophrenic patients in the UK. Br J Psychiatry 163:150\u2013154","journal-title":"Br J Psychiatry"},{"key":"BF02245620_CR4","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/0006-3223(91)90329-K","volume":"29","author":"BM Cohen","year":"1991","unstructured":"Cohen BM, Keck PE, Satlin A, Cole JO (1991) Prevalance and severity of akathisia in patients on clozapine Biol Psychiatry 29:1215\u20131219","journal-title":"Biol Psychiatry"},{"key":"BF02245620_CR5","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/0006-3223(94)90025-6","volume":"35","author":"M Dave","year":"1994","unstructured":"Dave M (1994) Clozapine-related tardive dyskinesia: a case report. Biol Psychiatry 35:886\u2013887","journal-title":"Biol Psychiatry"},{"key":"BF02245620_CR6","first-page":"589","volume":"46","author":"S Doepp","year":"1975","unstructured":"Doepp S, Muddeberg C (1975) Extrapyramidale symptom unter clozapin. Nervenarzt 46:589\u2013590","journal-title":"Nervenarzt"},{"key":"BF02245620_CR7","doi-asserted-by":"crossref","first-page":"722","DOI":"10.2165\/00003495-199040050-00007","volume":"40","author":"A Fitton","year":"1990","unstructured":"Fitton A, Heel RC (1990) Clozapine: a review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 40:722\u2013747","journal-title":"Drugs"},{"key":"BF02245620_CR8","first-page":"209","volume":"26","author":"Gerlach","year":"1979","unstructured":"Gerlach (1979) Tardive dyskinesia. Dan Med Bull 26:209\u2013245","journal-title":"Dan Med Bull"},{"key":"BF02245620_CR9","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1600-0447.1974.tb09706.x","volume":"50","author":"J Gerlach","year":"1974","unstructured":"Gerlach J, Koppelhus P, Helweg E, Monrad A (1974) Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 50:410\u2013424","journal-title":"Acta Psychiatr Scand"},{"key":"BF02245620_CR10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-1-4684-5038-5_6","volume-title":"Movement disorder","author":"J Gerlach","year":"1986","unstructured":"Gerlach J, Casey DE, Korsgaard S (1986) Tardive dyskinesia: epidemiology, pathophysiology and pharmacology. In: Shah NS, Donald AG (eds) Movement disorder. Plenum Press, New York, pp 119\u2013147"},{"key":"BF02245620_CR11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0447.1993.tb03366.x","volume":"87","author":"J Gerlach","year":"1993","unstructured":"Gerlach J, Korsgaard S, Clemmesen P, Lund Lauersen A-M, Magelund G, Noring U, Povlsen UJ, Bech P, Casey DE (1993) The St Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr Scand 87:244\u2013252","journal-title":"Acta Psychiatr Scand"},{"key":"BF02245620_CR12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1192\/bjp.152.2.253","volume":"152","author":"WM Glazer","year":"1988","unstructured":"Glazer WM, Morgenstern H, Niedzwiecki D, Hughes J (1988) Heterogeneity of tardive dyskinesia: a multivariate analysis. Br J Psychiatry 152:253\u2013259","journal-title":"Br J Psychiatry"},{"key":"BF02245620_CR13","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1192\/bjp.158.6.822","volume":"158","author":"WM Glazer","year":"1991","unstructured":"Glazer WM, Morgenstern H, Doucette JT (1991) The prediction of chronic persistent versus intermittent tardive dyskinesia: a retrospective followup study. Br J Psychiatry 158:822\u2013828","journal-title":"Br J Psychiatry"},{"key":"BF02245620_CR14","unstructured":"Guy W (1976), ECDEU Assessment Manual for Psychopharmacology. US Dept of Health and Human Services publication (ADM) 76-338, Rockville, pp 534\u2013535"},{"key":"BF02245620_CR15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ddr.430090106","volume":"9","author":"J Kane","year":"1986","unstructured":"Kane J, Woerner M, Lieberman J et al. (1986) Tardive dyskinesias and drugs. Drug Dev Res 9:41\u201351","journal-title":"Drug Dev Res"},{"key":"BF02245620_CR16","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H and the Clozaril Collaborative Study Group (1988) Clozapine for the treatment resistant schizophrenia: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789\u2013796","journal-title":"Arch Gen Psychiatry"},{"key":"BF02245620_CR17","first-page":"327","volume":"54","author":"JM Kane","year":"1993","unstructured":"Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA (1993) Does clozapine cause tardive dyskinesia? J Clin Psychiatry 54:327\u2013330","journal-title":"J Clin Psychiatry"},{"key":"BF02245620_CR18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/BF02245249","volume":"118","author":"M Kurz","year":"1995","unstructured":"Kurz M, Hummer N, Oberbauer H, Fleischhacker WW (1995) Extrapyramidal side effects of clozapine. Psychopharmacology 118:52\u201356","journal-title":"Psychopharmacology"},{"key":"BF02245620_CR19","first-page":"248","volume":"53","author":"H Levin","year":"1992","unstructured":"Levin H (1992) Should chronic treatment-refractory akathisia be an indication for the use of clozapine in schizophrenic patients. J Clin Psychiatry 53:248\u2013251","journal-title":"J Clin Psychiatry"},{"issue":"suppl","key":"BF02245620_CR20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/BF00442560","volume":"99","author":"J Lieberman","year":"1989","unstructured":"Lieberman J, Johns C, Coopet T, Pollack S, Kane J (1989) Clozapine pharmacology and tardive dyskinesia. Psychopharmacology 99 [suppl]:54\u201359","journal-title":"Psychopharmacology"},{"key":"BF02245620_CR21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.158.4.503","volume":"158","author":"JA Lieberman","year":"1991","unstructured":"Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J (1991) The effects of clozapine on tardive dyskinesia. Br J Psychiatry 158:503\u2013510","journal-title":"Br J Psychiatry"},{"issue":"suppl","key":"BF02245620_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","volume":"76","author":"O Lingj\u00e6rde","year":"1987","unstructured":"Lingj\u00e6rde O, Ahlfors UG, Bech P, Dencker ST, Elgen K (1987) The UKU side effect rating scale: a new comprehensive scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 76 [suppl]:1\u2013100","journal-title":"Acta Psychiatr Scand"},{"issue":"suppl","key":"BF02245620_CR23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1192\/S000712500029692X","volume":"160","author":"HY Meltzer","year":"1992","unstructured":"Meltzer HY (1992) Dimensions of outcome with clozapine. Br J Psychiatry 160 [suppl]:46\u201353","journal-title":"Br J Psychiatry"},{"key":"BF02245620_CR24","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00004714-198410000-00010","volume":"4","author":"HY Meltzer","year":"1984","unstructured":"Meltzer HY, Luchins DJ (1984) Effect of clozapine in severe tardive dyskinesia: a case report. J Clin Psychopharmacol 4:286\u2013287","journal-title":"J Clin Psychopharmacol"},{"issue":"suppl","key":"BF02245620_CR25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/BF00442563","volume":"99","author":"HY Meltzer","year":"1989","unstructured":"Meltzer HY, Bastani B, Young Kwon K, Ramirez LF, Burnett S, Sharpe J (1989) A prospective study of clozapine in treatment-resistant schizophrenic patients: I. preliminary report. Psychopharmacology 99 [suppl]:68\u201372","journal-title":"Psychopharmacology"},{"key":"BF02245620_CR26","first-page":"892","volume":"41","author":"HY Meltzer","year":"1990","unstructured":"Meltzer HY, Burnett S, Bastani B, Ramirez LF (1990) Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Commun Psychiatry 41:892\u2013897","journal-title":"Hosp Commun Psychiatry"},{"key":"BF02245620_CR27","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE, Gorham DR (1962) The brief psychiatric rating scale (BPRS). Psychol Rep 10:799\u2013812","journal-title":"Psychol Rep"},{"key":"BF02245620_CR28","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/archpsyc.1982.04290040052008","volume":"39","author":"DGC Owens","year":"1982","unstructured":"Owens DGC, Johnstone EC, Frith CD (1982) Spontaneous involuntary disorders of movement: their prevalence, severity and distribution in chronic schizophrenics with and without treatment with neuroleptics. Arch Gen Psychiatry 39:452\u2013461","journal-title":"Arch Gen Psychiatry"},{"key":"BF02245620_CR29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/archpsyc.1992.01820050009001","volume":"49","author":"D Pickar","year":"1992","unstructured":"Pickar D, Owen RR, Litmen RE, Konicki PE, Gutierrez R, Rapapoty MH (1992) Clinical and biological response to clozapine in patients with schizophrenia. Arch Gen Psychiatry 49:345\u2013353","journal-title":"Arch Gen Psychiatry"},{"key":"BF02245620_CR30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF00571412","volume":"56","author":"G Simpson","year":"1978","unstructured":"Simpson G, Lee JH, Shrivastava RK (1978) Clozapine in tardive dyskinesia. Psychopharmacology 56:75\u201380","journal-title":"Psychopharmacology"},{"key":"BF02245620_CR31","first-page":"603","volume":"26","author":"G Stille","year":"1971","unstructured":"Stille G, Lauener H, Eichenberger E (1971) The pharmacology of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4] diazepine (clozapine). II Pharmaco 26:603\u2013625","journal-title":"II Pharmaco"},{"issue":"suppl B","key":"BF02245620_CR32","first-page":"102","volume":"55","author":"CA Tamminga","year":"1994","unstructured":"Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao X-M (1994) Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 55 [9 (suppl B)]:102\u2013106","journal-title":"J Clin Psychiatry"},{"key":"BF02245620_CR33","first-page":"191","volume-title":"Abstracts from 9th World Congress of Psychiatry","author":"P Thomas","year":"1993","unstructured":"Thomas P, Lalaux N, Rogelet P (1993) Lasting dystonia with clozapine. In: Abstracts from 9th World Congress of Psychiatry, Rio, Brazil, p 191"},{"key":"BF02245620_CR34","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archpsyc.1987.01800220077011","volume":"44","author":"JL Waddington","year":"1987","unstructured":"Waddington JL, Youssef HA, Dolphin C, Kinsella A (1987) Cognitive dysfunctions, negative symptoms and tardive dyskinesia in schizophrenia: their association in relation to topography of involuntary movements and criterion of their abnormality. Arch Gen Psychiatry 44:907\u2013912","journal-title":"Arch Gen Psychiatry"},{"key":"BF02245620_CR35","volume-title":"Medstat: statistical program for the analysis of the results of controlled therapeutic trials and other types of clinical research","author":"HR Wulff","year":"1988","unstructured":"Wulff HR, Schlichting P (1988) Medstat: statistical program for the analysis of the results of controlled therapeutic trials and other types of clinical research. ASTRA Group A\/S, Albertslund, Denmark"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02245620.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02245620\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02245620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T17:33:26Z","timestamp":1557941606000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02245620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,3]]},"references-count":35,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[1996,3]]}},"alternative-id":["BF02245620"],"URL":"https:\/\/doi.org\/10.1007\/bf02245620","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,3]]}}}